아리바이오랩

261780KOSDAQ

54.3 / 100

Reference Date: 2026-09-08

Financial Score12.0 / 40

News Sentiment21.3 / 25

Momentum11.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Surged 24.7% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Chabaksin Research Institute is a biotech company specializing in the development of vaccines and immunotherapies using advanced technologies such as virus-like particles (VLP), liposomes, and immune checkpoint inhibitors (ICI). The company focuses on immunological research, antigen presentation, and apoptosis-related mechanisms to develop new drugs for infectious diseases and cancer.

Number of Employees

49people

Average Salary

63.4M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 15.004.0Point

PBR

7.08Industry Average 1.200.0Point

5.9x industry avg (risky)

ROE

-81.07Industry Average 8.000.0Point

Well below industry avg

Debt Ratio

14.65Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20250.0 / 10 points

Revenue Growth Rate

0.0 / 3

Avg ▼15.6% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼52.7% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -39.4% (declining, 3yr)

Detailed News Sentiment

2 totalPositive 2Neutral 0Negative 0Average Sentiment Score 85

Positive
아리바이오랩, 알츠하이머 백신 개발 착수…신경염증 공략
아리바이오랩의 알츠하이머 백신 개발 착수로 인해 회사의 혁신적 연구 성과와 잠재적 시장 영향력이 긍정적으로 평가됩니다.
Positive
아리바이오랩, mRNA 면역항암제 개발 본격화…대상포진 백신 2상도 순...
아리바이오랩이 mRNA 기반 면역항암제와 대상포진 백신 개발에 집중함으로써 신약 개발 진전을 보여주고 있다.

Detailed Momentum

52-week position3.0Point

52w lower range (27%)

Current 2,900Won52-week high 5,70052-week low 1,857

1-month return6.0Point

1m +24.73% (strong rise)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

1 totalPositive 0Neutral 1Negative 0

Neutral반기보고서 (2026.06)2026-08-14